Bradley Pharmaceuticals layoffs

Share this article:
Nearly two-thirds of Bradley Pharmaceuticals work force is expected to be let go following the company's acquisition by Nycomed.

According to a report in the Star-Ledger, Nycomed, a Swiss specialty drugmaker that has local offices in Florham Park, told New Jersey state officials that it plans to eliminate 196 jobs that were once based at Bradley's headquarters in Fairfield. The layoffs take effect April 30, according to information on the New Jersey Department of Labor's website.

When the $346 million deal was completed last month, Nycomed said it would transfer “key employees” of Bradley from Fairfield to Florham Park, which will be home to the Swiss company's PharmaDerm division. Prior to the sale, Bradley had roughly 300 employees.

An undisclosed number of layoffs were also made on Nycomed's side. The PharmaDerm unit will have 150 to 160 employees, some 30 to 35 of whom will work at Florham Park, the Star-Ledger reported.

The purchase of Bradley makes privately held Nycomed one of the top five companies selling prescription dermatology products.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...